Translating Advanced Microbiome Science into Clinical & Commercial Impact, to Build Investor Confidence and Deliver Safe, Effective Solutions for End Consumers.
Momentum is returning to microbiome-based therapies. Companies like Vedanta Biosciences, Siolta Therapeutics, Microbiotica and Seres Therapeutics are moving closer to commercialisation across C. diff, oncology and immune-related diseases. Recent financings, including mbiomics (€30M), Kanvas Biosciences ($48M) and EnteroBiotix (£19M), alongside the Gates Foundation’s $2.5 billion commitment to women’s health, signal growing confidence in the field.
But momentum alone isn’t enough. Unclear mechanisms, inconsistent clinical efficacy, and limited pharma and investor trust still stand between promising science and real-world patient impact.
That’s why the 11th Microbiome Movement USA Summit returns to Boston this November. You will join C-suite, VP and Director-level leaders across pioneering biopharma, regulators, and both microbiome-curious and first-time investors to answer one critical question:.
How do you translate microbiome biology into clinically validated, commercially viable therapies to effectively treat your indication of interest?
Don’t miss networking opportunities and insights from Ferring Pharmaceuticals, Nestlé Health Science, Vedanta Biosciences, MRM Health, Seventure Partners, the Gates Foundation, and more, as you discover how to demonstrate robust clinical efficacy, rebuild stakeholder confidence, and position your program for regulatory and commercial success.
A good collection of scientific talks from both gene editing tools and delivery methods.
2025 Attendee, Senior Scientist, BioNTech
This summit represents an important forum to align on how we collectively move genome editing therapies forward, from scientific innovation to safe, scalable clinical applications. I’m looking forward to sharing a risk-based view of off-target biology and learning how others are addressing the same regulatory and translational challenges across the field.
2026 Speaker, Senior Director, Genomics & Computational Biology, Beam Therapeutics
Good mix of talks that covered the genome editing field, with mostly cutting-edge material.
2024 Attendee, Professor, Translational Research, University of Pennsylvania
Explore the 2026 Event Guide
- Join >80% C-level, VPs, and Directors to identify and connect with key opinion leaders in the microbiome space
- See the LBP and FMT coverage to pinpoint sessions most relevant to your program
- See active investors and strategic partners attending to refine your funding and partnering strategy
- Pharma insights from Ferring and ex-Takeda leaders to understand how to secure pharma support
- Learn from Vedanta, MRM Health, and AOBiome to overcome clinical setbacks and scale microbiome-based therapies
2026 Speakers
Attending Companies Include
Explore Related Events
Explore the Agenda
Dive into real-world strategies tackling microbiome credibility, clinical efficacy, and regulatory hurdles so you can move your program forward with confidence.
Partner With Us
Position your solution at the centre of microbiome dealmaking as biotechs actively seek partners to validate, fund, and scale their programs.
Join Biopharma Experts
Connect with microbiome leaders across R&D, CMC, and BD to exchange insights, overcome shared challenges, and build partnerships that accelerate clinical and commercial success.